BPC-157 sits on the banned list of every drug-tested sport that follows the World Anti-Doping Agency (WADA) code. UFC, USADA, NCAA, and every Olympic-affiliated body enforce it. Several MMA fighters have tested positive and lost wins. That's the headline.
The reason matters more than the headline. WADA didn't ban BPC-157 because it doesn't work. WADA banned it because it does. This piece walks through the ruling, the science athletes were chasing in the first place, and the standard research cycle people still use it for off the field.
The WADA call: what S0 actually means
WADA keeps a list called the Prohibited List. It has 11 categories, S0 through S9 plus two P-categories. S0 is the catch-all at the top: any substance that has biological activity but isn't approved by any government health authority for human use.
BPC-157 fits S0 exactly. The animal data is solid. Some early human work exists. No country has approved it as a prescription drug. So WADA covers it under S0 by default, without needing to write a special rule.
The practical result: if you compete in a WADA-tested sport, BPC-157 is banned. UFC, US Olympic teams, NCAA athletes, World Athletics, FIFA-affiliated leagues, all follow the same list. Suspensions for testing positive run from 2 to 4 years.
What BPC-157 actually is
BPC-157 is a synthetic 15-amino-acid peptide. The sequence comes from a fragment of a larger protein first isolated from human gastric juice (stomach fluid). The acronym stands for Body Protection Compound.
It is the most-studied soft-tissue and gut research peptide in the published animal literature. The compound has been studied for decades in research models of tendon, ligament, bone, and gut tissue repair. That body of work is what put it on athletes' radar.
Why athletes wanted it (the recovery signal)
Animal research on BPC-157 reports faster soft-tissue research outcomes across several injury models. Tendon, ligament, muscle, and bone are the most-cited targets. A typical rat or rabbit study shows tissue repair markers landing days earlier in the BPC-157 group than the control.
For a pro athlete with a 6-month tendon injury and a season at risk, that signal is worth chasing. Several fighters and combat-sport athletes used it in the years before the ban tightened. The ones who got caught were the data point WADA used to make S0 enforcement public on the compound.
Mechanism in plain English
The proposed pathways span several cellular systems. The most cited in the literature:
- New capillary growth. BPC-157 appears to promote the formation of new tiny blood vessels at research sites, supporting local blood flow during repair.
- Growth factor interaction. Reported interaction with VEGF, EGF, and fibroblast growth factor in research models.
- Nitric oxide pathway. Modulation of the NO system, relevant to blood vessel and gut research.
- Lower inflammation signaling. Reported drop in inflammatory markers at soft-tissue research sites in animal models.
Unlike the weight-loss class (semaglutide, tirzepatide, retatrutide) where the mechanism is well-mapped through receptor binding, the BPC-157 literature is built on downstream observation rather than one single receptor. That's normal for compounds in the regenerative research category.
What is the standard BPC-157 research cycle structure?
| Phase | Duration | Daily dose | Frequency |
|---|---|---|---|
| Standard cycle | 4 weeks | 250 to 500 mcg | Once daily, or split AM/PM |
| Extended cycle | 6 weeks | 500 mcg | Split AM/PM (250 mcg each) |
| Back-to-back cycle | 2 x 4 weeks | 250 to 500 mcg | 4-week wash-out between cycles |
| Maintenance pulse | 2 weeks | 250 mcg | Quarterly, for ongoing soft-tissue research |
Subcutaneous (under the skin) injection close to the soft-tissue research site is the standard route. Many researchers run two back-to-back 4-week cycles with a 4-week wash-out for higher-load research targets.
What are the BPC-157 side effects from the research literature?
- Injection site response. Mild redness or tenderness at the shot site, usually gone within a few hours.
- Mild fatigue. Sometimes shows up in the first 3 to 5 days. Goes away on its own.
- Mild gut shifts. Some researchers note bowel pattern changes in the first week. Consistent with the compound's gut activity profile.
- Headache. Uncommon. Usually resolves with extra water.
The published research reports a low side effect profile. No serious adverse events show up in the small human observational data we know of, but that human dataset is small.
How do you reconstitute and store BPC-157?
Aion ships BPC-157 in 5 mg and 10 mg vials. Standard mix for the 5 mg vial: 2 mL of bac water, giving 2.5 mg per mL, or 25 mcg per insulin syringe unit. Full step-by-step in our reconstitution guide.
- Lyophilized, sealed: refrigerated at 2 to 8 C, stable for months
- Lyophilized, long-term: minus 20 C freezer for multi-year storage
- Reconstituted with bac water: refrigerated at 2 to 8 C, 4 to 6 week use window
What researchers track on a BPC-157 cycle
- Pain or limitation score at the research site, daily (1 to 10)
- Range of motion at the research site, weekly
- Sleep quality, daily via wearable
- Resting heart rate, weekly average
- Function test specific to the site (grip strength, for example), weekly
What is the BPC-157 bottom line?
BPC-157 is the workhorse soft-tissue research peptide. Short cycle, low side effect profile, simple dosing. The WADA ban is a signal that the recovery effect is taken seriously by people whose job is catching things that work. That doesn't make it approved for people. It just makes the research literature worth reading carefully.
If you compete in a drug-tested sport, the answer is no. Outside that frame, BPC-157 is the most accessible compound in soft-tissue research, with a short cycle, simple dosing math, and a well-mapped operational pattern. The full beginner injection walk-through lives at /blog/peptide-injection-101.